A Phase 4 clinical trial involving angiotensin II was listed as recruiting on October 16, 2026. The trial, titled "Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?", is registered under identifier NCT07295522. According to the listing, the study status is currently recruiting participants. The trial is categorized as Phase 4, indicating it involves further evaluation of an approved treatment approach. No results or outcome data have been posted for this trial at this time. The title suggests the study is examining pharmacological optimization strategies in heart failure prevention, with attention to potential differences between sexes, though no specific findings have been disclosed. Angiotensin II remains an approved compound. Readers interested in the background and regulatory context of angiotensin II can consult the compound overview for additional information.
Angiotensin II Trial on Heart Failure Sex Gap Now Recruiting
See the full angiotensin ii overview
Source: https://clinicaltrials.gov/study/NCT07295522